Divalproex sodium extended-release for the prophylaxis of migraine headache. Expert Opin Pharmacother 2003 Sep;4(9):1573-8
Date
08/29/2003Pubmed ID
12943487DOI
10.1517/14656566.4.9.1573Scopus ID
2-s2.0-0141740241 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
The Diamond Headache Clinic first began using valproic acid in 1984. Subsequently, a variety of open-label and then placebo-controlled trials were carried out with valproic acid, followed by an enteric-coated formulation known as divalproex sodium delayed-release. These trials demonstrated a consistent pattern of efficacy and the delayed-release form improved tolerability while offering a twice-daily dosing schedule. This led to the development of an extended-release formulation. This formulation further improved tolerability and led to a once-daily dosing. The pivotal trial conducted in patients with migraine with the extended-release formulation demonstrated efficacy similar to that seen with the delayed-release form.
Author List
Freitag FGMESH terms used to index this publication - Major topics in bold
Clinical Trials as TopicDelayed-Action Preparations
Drug Administration Schedule
GABA Agents
Humans
Migraine Disorders
Randomized Controlled Trials as Topic
Valproic Acid
